Skip to main content

Table 1 Distribution of patient, tumour, and treatment characteristics of invasive breast cancer according to the mode of detection

From: Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers

  SP group
(n = 878)
IC group
(n = 181)
NSP group
(n = 554)
SP vs. IC group SP vs. NSP group IC vs. NSP group
  n (%) n (%) n (%) p p p
Age        0.060 0.307 0.236
  > 65 years 319 (36.3) 52 (28.7) 186 (33.6)    
  ≤ 65 years 559 (63.7) 129 (71.3) 368 (66.4)    
TNM stage        < 0.001 < 0.001 < 0.001
 I 560 (63.8) 67 (37.0) 227 (41.0)    
 II 255 (29.0) 86 (47.5) 174 (31.4)    
 III 47 (5.4) 21 (11.6) 77 (13.9)    
 IV 9 (1.0) 7 (3.9) 65 (11.7)    
 Unknown 7 (0.8) 0 (0.0) 11 (2.0)    
Extent of disease        < 0.001 < 0.001 0.0014
 Tumor with local spread (any T/N0/M0) 647 (73.7) 105 (58.0) 315 (56.9)    
  T1 560 (86.6) 67 (63.8) 227 (72.1)    
  T2 78 (12.1) 31 (29.5) 71 (22.5)    
  T3 8 (1.2) 5 (4.8) 5 (1.6)    
  T4 1 (0.1) 2 (1.9) 12 (3.8)    
 Tumor with regional spread (any T/N+/M0) 215 (24.5) 69 (38.1) 163 (29.4)    
 Advanced cancer (any T/any N/M+) 9 (1.0) 7 (3.9) 65 (11.7)    
 Unknown 7 (0.8) 0 (0.0) 11 (2.0)    
SBR grade        0.001 0.022 0.147
 1 228 (26.0) 27 (14.9) 115 (20.8)    
 2 486 (55.4) 109 (60.2) 299 (54.0)    
 3 136 (15.5) 42 (23.2) 110 (19.9)    
 Unknown or not assessed 28 (3.2) 3 (1.7) 30 (5.4)    
Hormonal receptor status        < 0.001 < 0.001 0.171
 OR+/PR+ 633 (72.1) 105 (58.0) 331 (59.8)    
 OR+/PR- or OR-/PR+ 137 (15.6) 32 (17.7) 109 (19.7)    
 OR-/PR- 88 (10.0) 41 (22.7) 89 (16.1)    
 Unknown or not assessed 20 (2.3) 3 (1.7) 25 (4.5)    
Her-2 receptor status        0.350 0.068 0.899
 Positive 86 (9.8) 23 (12.7) 72 (13.0)    
 Negative 699 (79.6) 146 (80.7) 427 (77.1)    
 Unknown or not assessed 93 (10.6) 12 (6.6) 55 (9.9)    
Type of treatment        < 0.001 < 0.001 < 0.001
 Surgery ± RT 535 (60.9) 60 (33.2) 233 (42.1)    
 Surgery + CT ± RT 293 (33.4) 91 (50.3) 199 (35.9)    
 Neoadjuvant treatment a+ Surgery ± CT/RT 43 (4.9) 27 (14.9) 68 (12.3)    
 No surgery (refusal, palliative treatment) 3 (0.3) 3 (1.7) 45 (8.1)    
 Unknown 4 (0.5) 9 (1.6)    
Type of surgery        0.045 < 0.001 0.113
 Breast-conserving surgery 692 (78.8) 129 (71.3) 327 (59.0)    
 Mastectomy 178 (20.3) 49 (27.1) 171 (30.9)    
 Unknown or no surgery 8 (0.9) 3 (1.7) 56 (10.1)    
  1. Chi-square and Fisher’s exact test did not including any missing values
  2. SP group, patients detected by the screening programme; IC group, patients with interval cancer; NSP group, patients detected without participating in the screening programme; SBR, Scarff-Bloom-Richardson grade; OR, oestrogen receptor; PR, progesterone receptor; RT, adjuvant radiotherapy; CT, adjuvant chemotherapy
  3. aNeoadjuvant treatment include neoadjuvant chemotherapy (38/43 in SP group, 25/27 in IC group and 57/68 in NSP group) or neoadjuvant hormonotherapy (5/43 in SP group, 2/27 in IC group and 11/68 in NSP group). One patient in NSP group receive both neoadjuvant hormonotherapy and adjuvant chemotherapy